ODM 108
Alternative Names: ODM-108Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Orion
- Class Analgesics
- Mechanism of Action TRPA1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neuropathic pain
Most Recent Events
- 16 Aug 2016 Orion Corporation terminates the phase I FIMTRIP trial (In volunteers) in the Netherlands after August 2016(NCT02432664)
- 19 Jul 2016 Discontinued - Phase-I for Neuropathic pain in Netherlands (PO) because of findings concerning tolerability of ODM 108
- 29 Apr 2015 Phase-I clinical trials in Neuropathic pain (In volunteers) in Netherlands (PO) (NCT02432664)